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The twin-arginine protein translocation (Tat) system mediates transport of folded proteins 29 
across the cytoplasmic membrane of bacteria and the thylakoid membrane of chloroplasts. 30 
The Tat system of Escherichia coli is made up of TatA, TatB and TatC components. TatBC 31 
comprise the substrate receptor complex, and active Tat translocases are formed by the 32 
substrate-induced association of TatA oligomers with this receptor. Proteins are targeted to 33 
TatBC by signal peptides containing an essential pair of arginine residues. We isolated 34 
substitutions, locating to the transmembrane helix of TatB that restored transport activity to 35 
Tat signal peptides with inactivating twin arginine substitutions. A subset of these variants also 36 
suppressed inactivating substitutions in the signal peptide binding site on TatC. The 37 
suppressors did not function by restoring detectable signal peptide binding to the TatBC 38 
complex. Instead, site specific crosslinking experiments indicate that the suppressor 39 
substitutions induce conformational change in the complex and movement of the TatB subunit. 40 
The TatB F13Y substitution was associated with the strongest suppressing activity, even 41 
allowing transport of a Tat substrate lacking a signal peptide. In vivo analysis using a TatA-42 
YFP fusion showed that the TatB F13Y substitution resulted in signal peptide independent 43 
assembly of the Tat translocase. We conclude that Tat signal peptides play roles in substrate 44 
targeting and in triggering assembly of the active translocase.  45 
 46 
Significance statement  47 
The twin-arginine translocation (Tat) system transports folded proteins across the prokaryotic 48 
inner membrane and the thylakoid membrane of plant chloroplasts. Proteins are targeted to 49 
the Tat system by signal peptides containing a highly conserved twin arginine motif. We 50 
isolated suppressors in the TatB component that allowed a Tat substrate with a defective twin 51 
arginine motif to be transported. The strongest of these suppressors, TatBF13Y, resulted in 52 
the constitutive assembly of the Tat translocase in the absence of signal peptide binding. 53 
These results show that Tat signal peptides have two separable roles – they target their 54 
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passenger proteins to the Tat machinery but they also trigger the assembly of the active Tat 55 
transporter. 56 





A large proportion of prokaryotic proteins are trafficked into or across the cytoplasmic 60 
membrane. Extracytoplasmic proteins are synthesized with cleavable N-terminal signal 61 
peptides to address them to export machineries located in the cytoplasmic membrane. Signal 62 
peptides are generally between 20-30 amino acids in length and have a recognizable tripartite 63 
structure comprising a basic n-region, a hydrophobic h-region and a polar c-region with a 64 
signal peptidase cleavage site.  65 
The Sec pathway is the major route of protein export in most prokaryotes, transporting 66 
unfolded polypeptides across the cytoplasmic membrane. In bacteria it is comprised of a 67 
SecYEG channel complex and a peripheral membrane ATPase, SecA (see (1, 2) for recent 68 
reviews). The initial discovery of Sec components was driven by genetic approaches using 69 
Escherichia coli to isolate suppressors of defective Sec substrate proteins and inactive signal 70 
peptides (e.g. 3, 4). These genetic suppressors also contributed significantly to mechanistic 71 
understanding of Sec-dependent protein translocation (5-7). More recently it has been shown 72 
that Sec signal peptides have dual roles – they serve to target their passenger proteins to the 73 
Sec machinery (3, 8) but also to allosterically activate the SecY channel (9).   74 
The twin-arginine protein translocation (Tat) pathway operates in parallel to the Sec pathway 75 
to transport folded proteins across the prokaryotic cytoplasmic membrane and the thylakoid 76 
membrane of plant chloroplasts (10, 11). Proteins are targeted to the Tat pathway by N-77 
terminal signal peptides that contain a conserved twin arginine motif at the n-region/h-region 78 
boundary (12, 13; Fig 1A). The Tat system in the model bacterium E. coli requires three 79 
membrane-bound subunits, TatA, TatB and TatC (14-17). The TatB and TatC proteins form a 80 
multivalent complex that binds Tat substrates through their twin arginine signal peptides (e.g. 81 
(18-20). Numerous experiments have shown that the TatC component recognizes the twin 82 
arginine motif (21-26) whereas TatB is close to the signal peptide h-region (27, 28). Signal 83 
peptides have been shown to penetrate deeply into the TatBC complex (29) and in thylakoids 84 
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at least this deep-binding mode may be modulated by the transmembrane proton 85 
electrochemical gradient (PMF) (30).  86 
It is generally accepted that the TatA protein forms the protein-conducting element of the Tat 87 
pathway. TatA oligomers assemble at the substrate-bound TatBC complex, dependent on the 88 
PMF (27, 31-35). Current models for Tat transport propose that TatA oligomers either provide 89 
form-fitting channels of varying diameter that adapt to the size of the folded passenger domain, 90 
or that oligomeric assemblies of TatA cause a localized weakening of the membrane and 91 
transient bilayer disruption accompanied by substrate transport (reviewed in 10, 11). An 92 
implicit prediction of the latter model is that transient membrane rupture would be expected to 93 
be accompanied by ion leakage. 94 
In this study we have addressed the function of the twin-arginine signal peptide in the Tat 95 
transport process by isolating genetic suppressors that either restore transport to signal 96 
peptides harbouring transport inactivating twin arginine substitutions, or that restore Tat 97 
activity to a TatC variant that has an inactive signal sequence binding site. Our results 98 
identified a common set of substitutions, primarily located in the transmembrane helix of TatB 99 
that can suppress both types of transport defect. Biochemical analysis of Tat translocases 100 
harboring these substitutions indicates that at least one of them, TatB F13Y, promotes signal-101 
peptide independent TatA assembly. Our findings show that, like Sec signal peptides, Tat 102 





Single amino-acid substitutions in TatB permit export of twin-arginine substituted 106 
signal peptides. 107 
Previous genetic screens using maltose binding protein (21, 22) or GFP (23) fused to the Tat 108 
signal sequence of E. coli TorA identified mutations that were able to restore some level of 109 
Tat transport to fusions with export defective twin arginine substitutions. These substitutions 110 
were located towards the N-terminal end of the TatB transmembrane helix or within the 111 
cytoplasmic loops of TatC. To shed light on potential functions of signal peptides during Tat 112 
transport, we initiated an independent genetic screen using a native E. coli Tat substrate, 113 
AmiA, as our reporter. AmiA is an N-acetylmuramoyl-L-alanine amidase that remodels the cell 114 
wall during growth. In the absence of a functional Tat system, the cell envelope is impaired 115 
due to the inability to correctly localize AmiA and the related Tat substrate AmiC, rendering E. 116 
coli sensitive to killing by SDS (36). Utilizing a strain lacking chromosomal tat genes and 117 
amiA/amiC (37), co-production of plasmid-encoded AmiA (from the medium copy construct 118 
pSUAmiA; 36) alongside a separate plasmid, pTAT1d (producing TatABC from a compatible 119 
medium copy plasmid; 38), permits the strain to grow on LB medium containing 2% SDS (SI 120 
Appendix, Fig S1). We then mutated the consecutive arginines in the Tat signal peptide of 121 
plasmid-encoded AmiA to each of the amino acid pairs RD, RE, RH, RN, RQ, KH, KQ or HH. 122 
As expected, each of these substitutions abolished growth on SDS (SI Appendix, Fig S1).  123 
Next we screened a tatB mutant library, generated in pTAT1d by error-prone PCR, for clones 124 
that supported growth of strains carrying AmiA with variant signal peptides (38). Each AmiA 125 
twin arginine variant was challenged with this library, screening approximately 10,000 clones 126 
for each construct. In total across the screening campaign we isolated thirty individual clones. 127 
Upon re-screening twenty of these retained the ability to suppress the inactive signal peptide 128 
variant of AmiA against which they were originally isolated. These clones are listed in SI 129 
Appendix, Table S1. Substitutions appeared to cluster within the transmembrane region of 130 
TatB, including L9Q that appeared in seven of the clones and F13Y that occurred in five 131 
clones, whilst F6Y, E8K, L9P and L10P were each found once. It should be noted that E8K, 132 
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L9P and L9Q substitutions have previously been identified as suppressors of inactive signal 133 
peptides (21, 22). We also found clones, each isolated twice, that contained no substitutions 134 
in the transmembrane domain, where the first substitution was in the amphipathic helix of TatB 135 
(clones BRQ1, BRQ2, BRQ3 and BRQ5).      136 
We introduced the individual amino acid substitutions F6Y, E8K, L9P, L9Q, L10P, F13Y, K30I 137 
and I36N into TatB encoded within the tatABC operon on the very low copy number plasmid 138 
pTAT101 (39) and tested their ability to support export of wild type AmiA and to suppress each 139 
of the RD, RE, RH, RN, RQ, KH, KQ or HH AmiA signal sequence variants (Fig 1B, 1C, SI 140 
Appendix, Fig S2, Table 1). Each of the substitutions was able to support transport of wild type 141 
AmiA, but they varied in their ability to permit export of the AmiA signal sequence variants. For 142 
example the F13Y variant of TatB supported growth on SDS for all of the signal peptide 143 
variants tested, whereas the L9Q, L10P, K30I and I36N TatB substitutions could suppress 144 
some of the signal sequence variants but not KH, KQ and HH substitutions. To determine 145 
whether the suppression observed was specific for the AmiA signal peptide, we generated a 146 
further construct where the signal peptide of the Tat substrate SufI was fused to the mature 147 
portion of AmiA and the same twin arginine substitutions were introduced (SI Appendix, Fig 148 
S3, Table 1). The TatB variants generally showed the same pattern of suppression of SufI 149 
signal peptide substitutions, although the TatBL10P, K30I and I36N variants could not 150 
suppress RD or RE substitutions in the SufI signal peptide. 151 
 152 
A subset of TatB signal peptide suppressors also suppress TatC signal peptide binding 153 
site mutants. 154 
In a complementary approach we asked whether it was possible to select suppressors of 155 
defects in the signal peptide binding site on TatC. Residue F94 in E. coli TatC is highly 156 
conserved and lies within the signal peptide binding site (25, 40; Fig 2A), and substitution to 157 
other amino acids is poorly tolerated (41). We constructed substitutions of F94 to each of the 158 
small neutral amino acids Ala and Gly, helix breaking Pro, polar residues Ser and Gln, 159 
positively charged Arg and Lys and negatively charged Asp. These substitutions were 160 
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introduced into TatC encoded on both the medium copy plasmid pTAT1d and the very low 161 
copy plasmid pTAT101 that also carry wild type tatA and tatB. SI Appendix, Fig S4 shows that 162 
substitutions to Asp, Gln or Pro resulted in a complete inability of strain DADE (tatABCD, 163 
tatE; 42) to grow in the presence of SDS at both medium and very low copy number. We 164 
selected the F94Q substitution of TatC and constructed three mutant libraries in the pTAT1d 165 
vector by error prone PCR in an attempt to identify suppressors of this inactivating tatC 166 
mutation. LibC1 carried mutations in the first 93 codons of tatC, LibC2 carried mutations in 167 
tatC from residue 95 onwards and LibAB contained mutations in the tatA and tatB genes.  168 
A number of suppressors were identified from screening the LibC1 and LibC2 libraries for 169 
growth on SDS plates. However sequence analysis indicated that for each of these Tat active 170 
mutants there was substitution at the tatC F94Q codon to tatC F94Y, W or L codons. By 171 
contrast, after screening more than 180 000 clones from the LibAB library, eleven mutants 172 
were isolated which were able to rescue the growth defect of TatC F94Q on SDS plates, of 173 
which five were still able to support growth on SDS following fresh transformation of strain 174 
DADE with the isolated plasmid. These clones are listed in SI Appendix, Table S2. 175 
Interestingly, each of these suppressors encoded either TatB L10P, F13Y or I36N that had 176 
been identified in our prior screen for signal sequence suppressors. Introduction of each of 177 
these substitutions, individually, into the very low copy number pTAT101CF94Q plasmid 178 
supported growth of strain DADE on SDS-containing media (Fig 2B), indicating that these 179 
TatB variants are each able to rescue the Tat-inactivating F94Q TatC substitution. 180 
Since these three TatB substitutions that suppress the TatC F94Q defect were previously 181 
isolated as suppressors of inactive Tat signal sequences, we asked whether any of the other 182 
tatB signal sequence suppressors we had found could also rescue the TatC F94Q substitution. 183 
Fig 2C shows that in addition to L10P, F13Y and I36N, L9Q could also restore Tat activity to 184 
cells producing TatC F94Q. The location of each these residues on a model of TatB is shown 185 
in Fig 2D. We next asked the question whether any of these TatC F94Q suppressors could 186 
restore Tat activity to other inactivating substitutions in TatC. Fig 2E shows that two different 187 
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inactivating substitutions of E103 in the signal peptide binding site, either E103A or E103K 188 
(25, 40, 41; Fig 2A), could also be complemented by three of the four suppressors of tatCF94Q 189 
(I36N did not suppress these substitutions), but they could not restore Tat activity caused by 190 
inactivating TatC substitutions located outside the signal peptide binding site (SI Appendix, 191 
Fig S5). Finally we tested whether F94Q suppressing substitutions were additive, i.e. whether 192 
when combined they resulted in a stronger suppressing activity. However, SI Appendix, Fig 193 
S6A shows that none of the pairwise combinations we tested gave any suppression of 194 
tatCF94Q and, with the exception of the F13Y, I36N substitution which showed some 195 
suppression of the RN signal peptide variant, the combined suppressors lost suppressive 196 
function of RN or KK substitutions of the SufI signal peptide (SI Appendix, Fig S6B). We 197 
therefore conclude that the suppressor mutations, when combined, have detrimental rather 198 
than additive effects on suppression activity. 199 
 200 
The TatB F13Y and L9Q substitutions support export of AmiA lacking a signal peptide. 201 
The results above indicate that the TatBF13Y substitution is the strongest suppressor of 202 
inactive Tat signal peptides, allowing the E. coli Tat system to recognize all eight of the 203 
different twin arginine motif substitutions tested as well as suppressing the TatC F94Q 204 
mutation. We therefore tested whether more severe signal peptide defects could be 205 
suppressed by this TatB variant. Fig 2F shows that, remarkably, even after truncation of the 206 
signal peptide by removal of the h-region, or indeed complete removal of the entire signal 207 
peptide-coding sequence of AmiA, we could still detect some Tat-dependent translocation of 208 
the AmiA passenger domain in the presence of TatBF13Y. The TatB L9Q substitution, which 209 
was the strongest suppressor of signal peptide defects after F13Y, also supported some 210 
translocation of mature AmiA, however we were not able to detect export of mature AmiC in 211 
the presence of either of these two suppressor substitutions (SI Appendix, Fig S6C). We 212 
conclude that TatB L9Q and F13Y allow at least one Tat substrate to be transported 213 




Variant TatB proteins support good transport activity of a native Tat substrate but much 216 
poorer transport when the signal peptide is altered.  217 
We next addressed whether the TatB substitutions were detrimental to the activity of the Tat 218 
system. Using overproduced his-tagged, but otherwise native SufI as a substrate it was seen 219 
that mature SufI was clearly detected in the periplasmic fractions of all of the strains tested, 220 
although TatBI36N seemed to support only low levels of transport (SI Appendix, Fig S7A). 221 
However, we were unable to detect transport of the RD, RN or KQ signal peptide variants of 222 
SufI in the presence of TatBF13Y (SI Appendix, Fig S7B) or of a twin-lysine substituted his-223 
tagged CueO in the presence of TatBE8K or F13Y (Fig 3). It therefore appears that there is 224 
very low export efficiency of substrates with variant signal peptides in the suppressor mutant 225 
strains.  226 
 227 
The TatB suppressors do not restore biochemically detectable signal peptide binding 228 
to TatBC.  229 
We subsequently sought to understand the biochemical basis for the action of the TatB 230 
suppressors. Our initial hypothesis was that they acted to increase the affinity of the TatBC 231 
complex for the variant signal peptides, or to restore binding to complexes containing the TatC 232 
F94Q or E103A/E103K substitutions. First we produced his-tagged GFP with variants of the 233 
SufI signal peptide at its N-terminus and assessed how much TatBC could be co-purified with 234 
this from detergent-solubilized membrane fractions. Fig 4A shows that when the wild type 235 
signal peptide was fused to GFP, wild type TatBC or variants harbouring the TatB E8K, F13Y 236 
or I36N substitutions were co-eluted with his-tagged SufI-GFP. However no TatBC was 237 
detected when the RR motif in the signal peptide was mutated to RD, RN, or KK, even in the 238 
presence of the TatB suppressor substitutions (despite the fact TatBC and GFP were clearly 239 
present in all of the input samples; SI Appendix, Fig S8A and B). Very similar behavior was 240 
also seen when his-tagged AmiA variants were used as substrate for co-purification 241 
experiments (SI Appendix, Fig S9). Thus TatBC and TatBF13YTatC co-purified with the his-242 
tagged wild type AmiA precursor, but no TatBC was detected when RD, RN, KK or KQ 243 
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substitutions were introduced into the signal peptide, or when the AmiA signal peptide was 244 
lacking. We conclude that the TatB suppressors do not detectably restore binding of variant 245 
signal peptides to the TatBC complex. Since several TatB variants can transport substrates 246 
with defective signal peptides, but not without signal peptides (Fig 3), we infer that the 247 
defective signal peptides must still weakly interact with the TatBC complex at a level that is 248 
not detected by our co-purification assay. 249 
We then tested whether any of the four suppressors, TatB L9Q, L10P, F13Y and I36N, that 250 
allow Tat transport in the presence of the TatC F94Q and E103K mutations, acted to restore 251 
substrate binding to TatBC complexes containing these signal sequence binding site 252 
substitutions. Although high GFP fluorescence and strong TatBC signals were detected in 253 
whole cells (SI Appendix, Fig S8C and D), only wild type TatBC was found to co-purify with 254 
his-tagged SufIss-GFP (Fig 4B). Thus, as expected, TatC substitutions F94Q or E103K 255 
prevented co-purification of TatBC-substrate complex, consistent with loss of signal peptide 256 
binding detected for substitutions at these amino acid positions (25, 40). However, detectable 257 
signal peptide binding was not restored by introduction of the individual TatB suppressor 258 
substitutions. We conclude that the TatB suppressors do not act by rescuing signal peptide 259 
binding.   260 
 261 
The TatBC complexes harboring TatB suppressor substitutions are conformationally 262 
altered. 263 
We next investigated whether TatBC complexes could still be detected when any of the 264 
TatBL9Q, L10P, F13Y or I36N substitutions were present in TatB. Membranes harboring wild 265 
type TatA and TatC along with each of these TatB variants were solubilized with digitonin and 266 
analysed by blue-native gel electrophoresis (BN-PAGE). As shown in Fig 5A, the wild type 267 
TatBC complex solubilized with digitonin migrated close to the 440 kD marker, as reported 268 
previously (e.g. 43). The TatB L9Q, F13Y and I36N variants were also associated with a 269 
complex of apparently identical size to wild type TatBC, whereas for membranes producing  270 
TatBL10P, very little TatBC complex could be detected, even though both proteins were 271 
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solubilized from the membrane (SI Appendix, Fig S10). Interestingly, the L9Q and F13Y TatB 272 
substitutions also resulted in the appearance of a second band of apparently higher mass that 273 
was absent from the sample containing wild type TatBC (Fig 5A, B).  274 
We wondered whether this additional band might arise due to the presence of excess TatA 275 
bound to the variant complexes. However, blotting the BN gels for TatA showed the distinct 276 
TatA-laddering pattern reported previously (44, 45) was detectable for all of the samples, but 277 
there was no obvious TatA cross-reactive material migrating at the same position as the higher 278 
mass TatBC-containing complex (Fig 5B). To examine whether the presence of TatA was 279 
required for these higher molecular weight variant TatBC complexes to form, we repeated the 280 
BN-PAGE analysis in the absence of TatA (or its paralog TatE; 16). Surprisingly, this resulted 281 
in the apparent aggregation of the variant TatBC complexes, yielding a series of bands of 282 
apparent masses well above 440kDa that were not seen for the wild type (Fig 5C). We infer 283 
from this that there is a conformational alteration in the TatBC complex induced by the 284 
presence of the L9Q or F13Y TatB substitutions that in the absence of TatA causes further 285 
oligomerisation.  286 
Conformational alterations in the TatBC complex have been previously detected by disulfide 287 
crosslinking (46, 47). Cléon et al. (47) reported that when a Tat substrate was overproduced, 288 
a disulfide crosslink between M205C in transmembrane helix 5 of neighboring TatC proteins 289 
could be detected in vivo, suggesting the formation of a transient TatC dimer in response to 290 
substrate binding. Fig 5D confirms that dimerization through TatC M205C is not observed 291 
unless cells also harbor an overproduced Tat substrate, in this case CueO. The TatC M205C 292 
dimer induced by CueO is almost completely absent when the F94Q substitution is introduced 293 
into TatC, again supporting the conclusion that substrate binding promotes TatC dimerization 294 
(Fig 5D). Interestingly, however, when either the TatB L10P or F13Y substitutions were 295 
present, a TatC M205C crosslink was detected in the absence of overexpressed substrate. 296 
We wondered whether these TatB substitutions rendered the TatBC complex more responsive 297 
to the presence of endogenous substrates. To test this, we also introduced the signal peptide 298 
binding defective F94Q substitution into TatC M205C. However, as Fig 5D shows, the TatC 299 
13 
 
M205C dimer can still be detected in the presence of TatB L10P or F13Y substitutions, even 300 
when the F94Q inactivating substitution is present, and is therefore independent of signal 301 
peptide binding. We conclude that at least a subset of the TatB suppressors induce 302 
conformational changes in the TatBC complex, and that the TatBL10P and F13Y substitutions 303 
potentially mimic the substrate-bound form of the complex.  304 
 305 
The TatBF13Y substitution promotes signal peptide-independent oligomerisation of 306 
TatA in vivo. 307 
Substrate binding to the TatBC complex is a pre-requisite for the assembly of a TatA oligomer. 308 
TatA oligomer assembly in vivo can be followed by fluorescence microscopy in cells producing 309 
a chromosomally-encoded TatA-YFP fusion protein (34). When Tat substrates are present at 310 
native level, TatA oligomers are found with low frequency, but this frequency can be 311 
significantly increased by overproduction of a Tat substrate protein with a functional signal 312 
peptide (34, 35). This finding is confirmed in Fig 6A, where clusters of TatA-YFP can be seen 313 
in cells overproducing AmiA from a plasmid. As expected, introduction of the F94Q codon 314 
substitution into chromosomally-encoded tatC prevented the AmiA-induced clustering of TatA-315 
YFP resulting in a halo of delocalized TatA around the cell periphery (Fig 6A), consistent with 316 
the inability of the TatC variant to bind substrates. We next assessed whether any of the TatC 317 
F94Q suppressors, TatB L9Q, L10P, F13Y or I36N (introduced into chromosomal tatB) 318 
affected the oligomerisation of TatA-YFP (Fig 6B, SI Appendix, Fig S11). Remarkably we 319 
found that the presence of the TatB F13Y substitution promoted constitutive assembly of TatA-320 
YFP in the absence of overproduced Tat substrates (Fig 6B), and the TatA-YFP assemblies 321 
persisted even in the presence of the TatC F94Q substitution for this variant (but not for L9Q, 322 
L10P or I36N; SI Appendix, Fig S11). Taken together, these results indicate that the TatB 323 
F13Y substitution triggers signal peptide-independent assembly of TatA oligomers. 324 
 325 
No leak across the cytoplasmic membrane when cells produce the Tat system 326 
containing TatB F13Y. 327 
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One of the current models for Tat transport posits that TatA oligomers facilitate transport of 328 
substrates by causing a localized weakening of the bilayer and transient disruption (discussed 329 
in 10, 11). Such a mechanism might be expected to be accompanied by increased 330 
permeability of small molecules associated with assembled TatA. The availability of a TatB 331 
variant (F13Y) that causes TatA to accumulate in the assembled state provides an 332 
experimental tool to investigate this issue.  333 
First we asked whether overexpression of Tat systems containing the TatB suppressors L9Q, 334 
L10P, F13Y or I36N from an arabinose-inducible promoter had any effect on the growth rate 335 
of E. coli. Fig 7A shows that when production of each of these variant Tat systems was induced 336 
by the addition of arabinose, cells grew more slowly than when the wild-type Tat system was 337 
overexpressed, with the TatBL9Q substitution having a particularly detrimental effect on 338 
growth rate. This indicates that some level of toxicity is associated with overproduction of these 339 
variants. We next assessed whether the TatB variants facilitated membrane permeability 340 
using an osmotic lysis method previously used to monitor solute movement through the Sec 341 
protein transport channel (48). Here spheroplasts containing wild type or variant Tat 342 
translocases were diluted into an iso-osmotic solution of the uncharged sugar xylitol and 343 
permeation of xylitol into the cells was assessed by monitoring turbidity associated with 344 
osmotically-induced spheroplast lysis. Spheroplasts expressing a SecY variant that is known 345 
to increase permeability (48, 49) rapidly lysed following dilution into xylitol solution (Fig 7B). 346 
However, no lysis was observed for spheroplasts producing any of the variant Tat 347 
translocases, even those harboring the TatA-oligomerizing TatB F13Y variant (Fig 7B). 348 
Western blotting confirmed that the Tat proteins were present in these membranes (Fig 7C). 349 
These results show the TatA assemblies induced by the TatB F13Y substitution do not result 350 






In this work a genetic approach has been taken to shed light on functions of twin arginine 355 
signal peptides during Tat transport. Two complementary screens, the first to identify 356 
substitutions in TatB permitting export of substrates with inactivating substitutions at the signal 357 
peptide arginine pair, and the second to identify rescue mutations of the TatC signal peptide 358 
binding site converged on a similar group of tatB suppressors. Four TatB substitutions were 359 
identified – three in the transmembrane domain, L9Q, L10P and F13Y, and one in the 360 
amphipathic helix (I36N) that restored Tat transport in the presence of the inactivating TatC 361 
F94Q substitution. The same three substitutions in the transmembrane helix could suppress 362 
inactivating substitutions at E103, also in the signal peptide binding site. Of these three, the 363 
F13Y substitution displayed the strongest suppressing activity, allowing export all of the twin 364 
arginine substitutions tested, and even allowing some translocation of AmiA completely devoid 365 
of a signal sequence.   366 
A combined bioinformatics and mutagenesis approach has shown the TatB transmembrane 367 
helix to bind along transmembrane helix 5 of TatC (50), and this is consistent with in vitro 368 
disulfide crosslinking studies (25, 39). Signal peptide binding to the TatBC complex is 369 
suggested to cause movement of TatB from its resting state binding site on TatC to a site 370 
elsewhere on the protein. This is proposed to prime TatA to occupy the same binding site, 371 
which in turn triggers assembly of further TatA molecules to form the active translocase (50; 372 
Fig 8). After our biochemical experiments revealed that the suppressors did not function by 373 
restoring detectable binding of signal peptides to the TatBC complex (Fig 4, S9), we 374 
considered whether the TatB substitutions were mimicking the substrate-driven 375 
conformational changes which prime the translocase for TatA recruitment, but in the absence 376 
of substrate binding. Our analysis using BN-PAGE showed that the TatB L9Q, L10P and F13Y 377 
substitutions caused conformational alterations in the resting TatBC complex (Figure 5A,B). 378 
The complex containing the L10P substitution appeared more labile as very little full-sized 379 
TatBC complex could be detected, whereas the L9Q and F13Y substitutions yielded a subset 380 
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of TatBC complexes with apparently increased mass which may be indicative of altered 381 
subunit composition or significant conformational change. Substrate-induced conformational 382 
changes in the wild-type complex can also be monitored by appearance of a crosslink between 383 
cysteine residues at position 205 at the periplasmic end of TatC transmembrane helix 5. This 384 
residue forms part of the TatB resting-state binding site (50), so is occluded from dimerization 385 
with a neighboring TatC molecule in the resting state, but has been shown to dimerize in 386 
response to overproduction of a Tat substrate (39). Similarly, assembly of TatA-YFP oligomers 387 
(indicating assembled translocation sites) which can be monitored by fluorescence 388 
microscopy is only seen for the wild-type translocase upon overproduction of Tat substrates 389 
(34). For one of the TatB substitutions, F13Y, both TatC M205C dimerization and TatA-YFP 390 
assembly were observed not only in the absence exogenous substrates, but also in the 391 
presence of a TatC F94Q substitution which disrupts interaction with signal peptides. We 392 
therefore conclude that TatB F13Y has decreased affinity for the ‘resting’ TatC binding site, 393 
and an increased affinity for the ‘activated’ binding site, such that it is able to trigger recruitment 394 
of TatA and transport of precursors in the absence of signal peptide binding. For the other 395 
TatB variants we propose that each differs in affinity for the resting and activated binding sites, 396 
leading to slight differences in conformation for these translocases, and we assume that in 397 
these cases, weak residual binding of a signal peptide lacking its twin arginine motif is 398 
sufficient to trigger TatA recruitment, whereas in the wild-type system the higher energy of 399 
binding of the twin arginine residues are strictly required for this. Hence the signal peptide 400 
plays two distinct roles- in precursor targeting and translocase activation.   401 
A favored model for Tat-mediated protein translocation is that protein passage across the 402 
membrane is facilitated by bilayer disruption arising from TatA oligomerization. Interestingly, 403 
it was noted that there was a reduced growth rate associated with overproduction of Tat 404 
systems containing TatB suppressors, including F13Y, suggesting apparent toxicity. However, 405 
no leak of the small uncharged sugar, xylitol, could be detected in membranes harboring Tat 406 
complexes containing TatB F13Y. This may suggest the presence of a substrate precursor is 407 
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necessary to provide the force required to disrupt the bilayer. Alternatively, it remains possible 408 
that the foci of TatA-YFP observed in cells producing TatBF13Y do not correspond to fully 409 
assembled translocases and that further recruitment of TatA(-YFP) (for example mediated by 410 
the folded mature domain of a Tat substrate (51)) is required. Indeed the export of mature 411 
AmiA in the presence of the TatB F13Y substitution might suggest that some Tat substrates 412 
have internal targeting information.   413 
In summary, our findings support the notion that Tat signal peptides have two distinct roles. 414 
They serve to target their passenger domains to the export machinery, but also to trigger 415 
assembly of the active translocase. The isolation of substitutions in the Tat machinery that 416 
bypass these steps should prove very useful to dissect the mechanism by which folded protein 417 
translocation is achieved.   418 
  419 
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Materials and Methods 420 
 421 
Strain construction. The E. coli strains used in this work are listed in SI Appendix, Table S3. 422 
Strain JM109 was used for regular cloning and transformation of Quickchange products, and 423 
ultracompetent cells of XL10-Gold® (Agilent) were used for construction of the random 424 
mutagenesis libraries. 425 
Strain DADE (as MC4100, ∆tatABCD, ∆tatE (42)) was used as the background strain for Tat 426 
transport activity tests and production of Tat proteins for membrane protein extraction, in vivo 427 
disulfide crosslinking and Blue-Native PAGE, with the exception of Fig 3 where strain M∆BC 428 
(MC4100 ∆tatBC; 33) was used. Strain DADE-P (as DADE, pcnB1 zad-981::Tn10d (Kanr); 429 
(52)) was used to co-produce TatB and TatC along with AmiA for co-purification experiments. 430 
Strain MCDSSAC ∆tatABC (37), in which the 2-33 codon of amiA and 2-32 codons for amiC 431 
are deleted and the tatABC operon was replaced with an apramycin resistance cassette, was 432 
used as the background strain for AmiA signal sequence library screening and to analyse 433 
transport of AmiA mediated by AmiA or SufI signal peptide variants. 434 
Transport of AmiA mediated by signal sequence truncations was assessed in strain MC4100 435 
∆amiA ∆amiC ∆tatABC, which was constructed as follows. The amiA:kanr  allele from the 436 
Keio collection (53) was moved into MC4100 by phage P1 transduction, after which the  437 
kanamycin resistance cassette was eliminated according to (54). Subsequently the amiC 438 
deletion was introduced and the kanamycin cassette subsequently eliminated using the same 439 
approach. Finally, the tatABC::Apra allele was introduced from strain BW25113 440 
tatABC::Apra (54) by P1 transduction. Strain BW25113 ∆glpF ∆tatABC was used in osmotic 441 
lysis experiments and was constructed by P1 transduction of the glpF:kanr  allele from the 442 
Keio collection (53), elimination of the kanamycin resistance and P1 transduction of the  443 
tatABC::Apra allele as described above. 444 
Strain AyBCE (34), which lacks tatA at the native locus and has a tatA-YFP fusion integrated 445 
into the chromosomal att site, was used in fluorescence imaging. Chromosomal point 446 
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substitutions in tatB and tatC were introduced into this strain via plasmid pMAK-AupBC and 447 
its variants using the approach of Hamilton et al. (55).  448 
Strain BL21(DE3) ∆tatABC was used to co-produce TatB and TatC along with SufIss-GFPhis 449 
for the co-purification experiments. This strain is a derivative of BL21(DE3) where the tatABC 450 
genes have been replaced with the apramycin resistance cassette, and was constructed by 451 
recombination as described previously (56).  452 
 453 
Plasmid construction. The plasmids used and constructed in this work are listed in SI 454 
Appendix, Table S4. All point mutations in plasmids, as well as insertion of the flag sequence 455 
to create p101C*BCflag, were introduced by Quickchange site-directed mutagenesis 456 
(Stratagene) using the primers listed in SI Appendix, Table S5.  457 
Plasmids pTAT101 (39) and pTAT1d (38) were used to express tatABC under the control of 458 
the native tatA promoter at very low and medium copy number, respectively. pTAT101 cys 459 
less (47) was used as the backbone to introduce single cys substitutions for in vivo disulfide 460 
crosslinking experiments. Plasmid pTATBC1d encodes TatBC and was constructed following 461 
amplification of tatBC pTAT1d using primers STIPE-ISH and pT7.5R (SI Appendix, Table S5) 462 
was digested using BamHI and PstI and cloned into similarly digested pUNIPROM (57). 463 
Plasmid pBADTatABChis codes for tatABC with a hexahistag coding sequence at the 3’ end 464 
of tatC in pBAD24 (58). It was constructed following amplification of tatABChis from pUNITAT2 465 
(59), digestion with NcoI and XbaI and cloning into similarly digested pBAD24. 466 
pSUAmiA (36) was used to produce full-length AmiA from a vector specifying chloramphenicol 467 
resistance. pSUSufIss-mAmiA was used to produce SufIss-mAmiA and was constructed 468 
following separate amplification of DNA encoding the SufI signal sequence including the sufI 469 
ribosome binding site using primers SufIssFE and SufIssR, and  the mature region of AmiA 470 
(mAmiA) using primers AmiA-mF and AmiA-mRX from the chromosome, and fusing the two 471 
fragments by overlap extension PCR according to reference (60). The resultant DNA fragment 472 
was then cloned into the pSU18 vector (61) using EcoRI and HindIII sites to generate 473 
pSUSufIss-mAmiA plasmid. Plasmids pSUSufIssnoH-mAmiA were used for production of 474 
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truncated SufIss-mAmiA lacking the signal peptide h-region. It was constructed by removal of 475 
codons 11-21 of the SufI signal sequence via Quickchange using pSUSufIss-mAmiA as 476 
template with primers SufI-noHF and SufI-noHR. pSUmAmiA was used to produce signal-less 477 
AmiA and was constructed as follows. A DNA fragment containing the ribosome binding site 478 
of amiA and the coding sequence for mature AmiA was amplified using pSUAmiA as template 479 
with primers AmiA-nossFE and AmiA-mRX. The DNA fragment was subsequently cloned into 480 
pSU18 using EcoRI and HindIII sites to generate pSUmAmiA. To express the mature domains 481 
of AmiA or AmiC from pQE70, DNA covering these regions were amplified with primer pairs 482 
mAmiA-SphI-F/AmiAnostopBamHI-R or mAmiC-SphI-F/AmiCnostopBamHI-R, respectively, 483 
using chromosomal DNA as template. The DNA fragments were digested with SphI and 484 
BamHI and cloned into SphI/BglII digested pQE70 vector (Qiagen, Manchester, UK). For 485 
fractionation experiments, SufI was produced with a C-terminal histag from pQE80 (Qiagen, 486 
Manchester, UK). It was cloned by excision of DNA covering a C-terminally his-tagged SufI 487 
from pQE60-SufI (62) as an NheI-XhoI fragment and ligation into similarly digested pQE80. 488 
Plasmid pMAK-AupBC was used to introduce the mutations into the AyBCE chromosome and 489 
was constructed by amplification of 500 bp of tatA upstream DNA from the chromosome of 490 
strain AyBCE using primers TatAup1-XbaI and TatAup2-ClaI, which was cloned into 491 
pBluescript KS(+) using XbaI and ClaI sites to give pKS-Aup. Next a DNA fragment covering 492 
the whole of tatBC was amplified from the chromosome of AyBCE strain with primers 493 
TatA6B7-ClaI and TatCrev-KpnI, and cloned into pKS-Aup using ClaI and KpnI sites to 494 
generate pKS-AupBC. Subsequently the DNA covering the tatA upstream sequence along 495 
with tatBC was excised using XbaI and KpnI and cloned into similarly digested pMAK705 (55) 496 
to give pMAK-AupBC. 497 
Plasmid pFAT75∆A-BC, which is a pQE-based plasmid expressing TatB and TatC without a 498 
histag (19), and pSufIss-GFPhis, which is a pCFDuet-based plasmid expressing synthetic SufI 499 
signal sequence-fused GFP with a histag at its C-terminus under the control of T7 promoter, 500 
were used in co-purification experiments. Plasmid pFAT75∆A-BC-AmiAhis coproduces 501 
untagged TatBC along with his-tagged AmiA and was constructed as follows. A DNA fragment 502 
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covering amiA was amplified from MC4100 genomic DNA using primers AmiAFATApaI-F and 503 
AmiAnostopBamHI-R, digested with ApaI and BamHI and cloned into ApaI - BglII digested 504 
pFAT75-SufIhis (47). pFAT75∆A-BC-mAmiAhis was constructed similarly, using primer 505 
mAmiAFATApaI-F and AmiAnostopBamHI-R to amply DNA covering the mature region of 506 
AmiA.  507 
 508 
Mutant library construction and screening. 509 
To screen for Tat signal sequence suppressors, substitutions of the twin arginine sequence of 510 
the AmiA signal peptide (to -RD, -RE, -RN, -RQ, -RH, -HH, -KH and –KQ) were constructed 511 
in the pSUAmiA plasmid. The resulting plasmids were individually introduced into strain 512 
MCDSSAC ∆tatABC and each resulting strain served as host to screen an existing tatB mutant 513 
library (in plasmid pTAT1d, 600,000 individual clones, 0.25% error rate, (38)).  514 
To screen for suppressors of the TatC F94Q substitution, three separate mutagenesis 515 
libraries, each of which carried the tatC F94Q codon substitution, were constructed that 516 
contained random mutations in either tatAB, codons 1-93 of tatC (tatC1) or codons 95-258 of 517 
tatC (tatC2), respectively using a modified MEGAWHOP (megaprimer PCR of whole plasmid) 518 
method as described (63). DNA fragments of tatAB, tatC1 and tatC2 containing random 519 
mutations were generated using error-prone PCR. Error-prone PCR was carried out in 1x 520 
GoTaq buffer, 7mM MgCl2, 0.2 mM dATP, 0.2mM dGTP, 1mM dCTP, 1mM dTTP, 0.4 μM 521 
each primer, 0 to 0.1 mM MnCl2, 50 ng pTAT1dCF94Q plasmid as template and 5 U GoTaq® 522 
DNA Polymerase (Promega) in a total volume of 50 μl using a PCR program: 94 °C for 2min 523 
followed by 20 cycles of incubation at 94 °C for 30s, 50 °C for 30s, and 72 °C for 3min, and a 524 
final incubation at 72 °C for 5min. Primer pairs TatA-FB and TatB-RS were used to amplify 525 
tatAB, TatCm6 and TatC93R to amplify tatC1 and TatC95F and TatCR1d were used to amplify 526 
tatC2. The DNA fragments were then used as megaprimers to amplify the whole plasmid, 527 
which was carried out in a 50 μl mixture containing 1x Herculase II reaction buffer, 0.5 mM 528 
each dNTP, 100ng pTAT1dCF94Q plasmid as template, 500 ng DNA fragment obtained 529 
above as megaprimers and 5 U Herculase II Fusion DNA Polymerase (Agilent) using the PCR 530 
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program : incubation at 68 °C for 5min, 95 °C for 2min, followed by 20 cycles of incubation at 531 
95 °C for 30s, 55 °C for 30s, and 68 °C for 6min. The resultant whole plasmid PCR products 532 
were digested with Dpn I to remove the template DNA and incubated with T4 polynucleotide 533 
kinase and T4 DNA ligase to repair the nicks. Finally, the whole plasmids were separately 534 
transformed into XL10-Gold® Ultracompetent Cells (Agilent) resulting in three mutagenesis 535 
libraries. Subsequent sequencing of 10 randomly selected colonies from each library revealed 536 
an average error rate of approximately 2 nucleotides per 1000 base pair. Screening of these 537 
three libraries was carried out in strain DADE (tatABCD, tatE). 538 
For screening experiments the libraries were transformed into the respective host strains and 539 
subsequently plated onto solid LB medium containing appropriate antibiotics and 2% SDS for 540 
selection. Colonies able to grow under these conditions were isolated, the mutations in the tat 541 
gene(s) identified by sequencing and retested for growth in the presence and absence of 2% 542 
SDS. To further verify isolated candidates, individual mutations were introduced into low copy 543 
number plasmid pTAT101 by site-directed mutagenesis and the activity was again assessed 544 
on 2% SDS-containing plates. 545 
 546 
Protein methods. For co-purification of TatBC-substrate complexes, cultures of strain 547 
BL21(DE3) ∆tatABC harboring pFAT75∆A (or a point-substituted variant) and pSufI-GFPhis 548 
were incubated at 37°C for 7 hours with shaking, after which they were supplemented with 549 
0.2mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated for a further 17 hours at 550 
37°C. The cells were subsequently harvested and resuspended in 1 x PBS, the fluorescence 551 
intensity of the suspension was recorded, after which the cells were re-pelleted, resuspended 552 
in 2 x lysis buffer (100 mM NaH2PO4 pH 8.0, 600 mM NaCl, 40 mM imidazole, 50 mg lysozyme, 553 
80 U benzonase, and protease inhibitor) and mixed gently at room temperature for one hour. 554 
Cells were snap frozen at -80°C, thawed at room temperature and an equivalent amount of 555 
2.5% digitonin was added and the sample gently mixed at room temperature for one hour. Cell 556 
debris was pelleted by centrifugation and the supernatant was transferred to a 96-well plate 557 
and mixed with 20 μl Ni-NTA Magnetic Agarose Beads (Qiagen) for one hour. After the beads 558 
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were washed three times with wash buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl , 40 mM 559 
imidazole, 0.03 % digitonin), bound proteins were eluted with 50 μl elution buffer (50 mM 560 
NaH2PO4, pH 8.0, 300 mM NaCl , 250 mM imidazole, 0.03 % digitonin). 561 
In vivo disulfide crosslinking was carried out in strain DADE harboring pTAT101 cys less 562 
CM205C, as described in (47). Blue-Native PAGE was undertaken according to (47, 64). 563 
Subcellular fractionation was according to (65). Preparation of membrane fractions was as 564 
described previously (39). For analysis of SufI export, E. coli strain DADE harboring wild-type 565 
or signal peptide variants of pQE80SufIhis alone or alongside wild-type or TatB variants of 566 
pTAT101 was cultured in the presence of 1mM IPTG until OD600 of 1 was reached. Samples 567 
(equivalent to 150 μl of whole cells from an OD600 = 1, or periplasm fractions from the 568 
equivalent of 300 μl of cells from an OD600 = 1) were separated by SDS PAGE and analysed 569 
by Western blot with anti-6X His tag® or anti-RNA polymerase  subunit antibodies 570 
(cytoplasmic control protein). For analysis of CueO export, strain M∆BC harbouring wild-type 571 
and KK variants of pQE80-CueO alongside wild-type, tatBE8K or tatBF13Y variants of 572 
p101C*BCflag were cultured and fractionated as previously described (34). Immunoblotting 573 
was according to the methodology of (66), and antibodies to TatA, TatB and TatC have been 574 
described previously (47, 67). Anti-6X His tag® antibody (HRP-conjugated) was purchased 575 
from Abcam (Cambridge, UK, catalog number ab184607), anti-DnaK mouse monoclonal 576 
8E2/2 antibody was also from Abcam (catalog number ab69617) and a mouse monoclonal 577 
anti RNA polymerase -subunit antibody was purchased from NeoClone Biotechnology 578 
(Madison, USA; catalog number W0023). Secondary antibodies were goat anti-Rabbit IgG 579 
(HRP Conjugate, catalog number 170-6515) or Goat Anti-Mouse IgG (HRP conjugate, catalog 580 
number170-6516), both from Biorad (Hemel Hempstead, UK). Immunoreactive bands were 581 
visualized with the Clarity Western ECL Substrate Kit (BioRad) and captured either on light-582 




Cell permeability experiments. Cell permeability experiments were performed according to 585 
(48). Briefly, cells were grown aerobically at 37°C with 1:100 inoculation of an overnight culture 586 
for 2 hours. Production of TatABC harboring TatB variants and of SecY(∆plug)EG was induced 587 
by addition of 0.2% arabinose at 37°C for 3 hours. Subsequently, the OD600nm of each sample 588 
was normalized using LB, a small volume was withdrawn for Western blotting and equal 589 
volumes of each culture were then harvested and resuspended in fractionation buffer (50 mM 590 
Tris-HCl buffer, 20% sucrose, pH 7.5, 5 mM EDTA, 0.6 mg/ml lysozyme) and incubated at 591 
room temperature for 20min to obtain spheroplasts. The spheroplast samples were then 592 
adjusted to the same OD600 and a 19-fold excess of 0.616 M xylitol solution was added. The 593 
samples were rapidly transferred to a 96-well plate and OD600 was measured every 30 594 
seconds for 300 seconds.  595 
 596 
Fluorescence microscopy. Cells were prepared for fluorescence microscopy and imaged as 597 
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Figure Legends 613 
 614 
Figure 1. Isolation of signal sequence suppressors in tatB. A. Schematic representation 615 
of a twin arginine signal peptide. The signal peptide sequences of E. coli Tat substrates SufI 616 
and AmiA are given underneath, with residues matching the Tat consensus motif in red, the 617 
consecutive arginines in red underline and the signal peptidase cleavage site in black 618 
underline. B and C. An example of screening results. Growth of MCDSSAC ∆tatABC 619 
coproducing the indicated TatB variants (with wild type tatA and tatC) from pTAT101, 620 
alongside B. the HH or C. RE-substituted signal peptide variants of AmiA, on LB agar 621 
supplemented with chloramphenicol and kanamycin, with or without the addition of 2% SDS 622 
as indicated. An 8l aliquot of each strain/plasmid combination following aerobic growth to an 623 
OD600 of 1.0 was spotted and incubated for 16 hr at 37°C.  624 
Figure 2. Isolation of suppressors of the TatC F94Q inactivating substitution. A. Model 625 
of E. coli TatC (from (47)) showing the location of the F94 and E103 residues (in red) that form 626 
part of the signal peptide binding. B., C. and E. Growth of DADE (tatABCD, tatE) 627 
coproducing wild type TatA alongside; B. and C. F94Q-substituted TatC or E. E103A-628 
substituted TatC, and the indicated substitution in TatB from plasmid pTAT101 on LB agar or 629 
LB agar containing 2% SDS. D. Structure of E. coli TatB (from (68)) with the locations of the 630 
TatCF94Q suppressor substitutions shown in red. F. Strain MC4100 ∆amiA ∆amiC ∆tatABC 631 
coproducing the indicated TatB variants (with wild type tatA and tatC) from pTAT101, 632 
alongside either a signal peptide variant of SufI lacking the h-region fused to the AmiA mature 633 
domain, or the mature AmiA domain alone on LB agar or LB agar containing 1% SDS. For all 634 
growth tests, a single colony of each strain/plasmid combination was resuspended in 30l of 635 
PBS and an 8l aliquot was spotted onto LB agar supplemented with appropriate antibiotics, 636 




Figure 3. TatB suppressors support export of a Tat substrate with its native signal 639 
peptide. E. coli strains producing native levels of TatA, TatC and the indicated TatB variants, 640 
and overproducing his-tagged CueO with a wild-type (top panel) or KK-substituted (bottom 641 
panel) signal peptide were fractionated into whole cell (W), spheroplast (S) and periplasm (P) 642 
fractions. Equivalent amounts of each fraction were separated by SDS PAGE and analysed 643 
by Western blot with antibodies against CueO and the cytosolic marker DnaK.  644 
Figure 4. The TatB suppressors do not restore signal peptide binding to the TatBC 645 
complex. A. C-terminally his-tagged GFP with the wild type (RR) or twin-arginine substituted 646 
SufI signal peptide at its N-terminus, as indicated, was purified by magnetic nickel beads from 647 
digitonin–treated cell extracts co-expressing TatC along with either wild type TatB or the E8K, 648 
F13Y or I36N substituted variants. B. C-terminally his-tagged GFP with the wild type SufI 649 
signal peptide at its N-terminus was purified by magnetic nickel beads from digitonin–treated 650 
cell extracts co-expressing TatB and TatC with the indicated amino acid substitutions. For A. 651 
and B. the elution fractions from each sample were normalized for GFP fluorescence and an 652 
equivalent amount of purified SufIss-GFPhis was loaded onto SDS-PAGE (4-15% Mini-653 
PROTEAN® TGX™ precast gradient gel) followed by western blot using TatB and TatC mixed 654 
antibodies.  655 
Figure 5. A constitutive disulfide crosslink and aberrant Blue-native PAGE migration 656 
induced by a subset of TatB suppressors. A-B. Membranes from E. coli strain DADE 657 
(tatABCD tatE) producing the indicated TatB variants alongside wild-type TatA and TatC 658 
from plasmid pTAT1d were solubilized by addition of 2% digitonin and analysed by BN-PAGE 659 
(4-16% Bis-Tris NativePAGE gels) followed by Western blot with anti-TatA, anti-tatB or anti-660 
TatC antibodies as indicated. 20 g solubilized membrane was loaded in each lane. C. 661 
Membranes from strain DADE producing the indicated TatB variant alongside wild-type TatC 662 
from plasmid pTATBC1d were solubilized and analysed as in A-B. D. Whole cells of DADE 663 
harboring pTAT101 co-producing either wild type TatA, the M205C single cysteine variant of 664 
TatC and the indicated substitution in TatB, or wild type TatA, the TatC F94Q M205C variant 665 
28 
 
of TatC and the indicated substitution in TatB were subjected to oxidizing (O) or reducing (R) 666 
conditions. Where indicated the additional plasmid pQE80-CueO, (producing His-tagged 667 
CueO) was also present. Membranes were prepared from equal quantities of cells following 668 
treatment and equivalent amounts of material from each sample were resolved by non-669 
reducing SDS-PAGE (12% acrylamide). TatC was visualized by western blotting using an anti-670 
TatC antibody and CueO-His with an anti-His antibody. 671 
Figure 6. The TatB F13Y substitution promotes constitutive oligomerisation of TatA in 672 
vivo. Fluorescence images of TatA-YFP in representative cells of A. strains AyBCE or 673 
AyBCF94QE (encoding the TatC F94Q substitution in chromosomal tatC) in the presence 674 
(pAmiA) or absence of plasmid-encoded wild type AmiA, as indicated. Production of AmiA was 675 
induced by addition of 1mM IPTG to mid-log cell cultures 45 min before harvesting. B. strains 676 
AyBF13YCE (encoding the TatB F13Y substitution in chromosomal tatB) and AyBCF94QE 677 
(encoding the TatB F13Y substitution in chromosomal tatB, alongside the TatC F94Q 678 
substitution in chromosomal tatC). Representative micrographs are shown for each sample; 679 
Scale bar: 1 μm. 680 
Figure 7. No detectable leak of xylitol across the cytoplasmic membrane when cells 681 
produce Tat translocases harboring TatB suppressors. A. Overnight cultures of E. coli 682 
strain BW25113 ∆glpF ∆tatABC harboring pBAD24 encoding TatA and TatC-his along with 683 
wild type TatB or each of the L9Q, L10P, F13Y or I36N point substitutions, were subcultured 684 
at 1:100 dilution into fresh LB medium containing ampicillin, which was supplemented after 685 
120 min with 0.2% of glucose or arabinose, as indicated. Growth of the strains was followed 686 
for a further 6.5h. Error bars represent standard deviation, n = 3 (biological replicates). B. The 687 
same strain and plasmid combinations as in part A, alongside BW25113 ∆glpF harboring 688 
pBAD22SecY(∆plug)EG. were subcultured and supplemented with 0.2% of arabinose as 689 
described in part A and grown for a further 3 h after which spheroplasts were prepared and 690 
incubated in the presence of xylitol. C. An aliquot of each sample producing plasmid-encoded 691 
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Tat proteins was analysed by SDS PAGE and western blotting to confirm expression of TatA, 692 
TatB and TatC-his. 693 
Figure 8. Tat translocases containing TatB suppressor variants may more readily 694 
transition to the signal peptide-activated state. Top panel: Model for Tat transport. A signal 695 
peptide bound through its n-region to the cytoplasmic surface of TatC (step 1) transitions to a 696 
deep binding mode (step 2). The deep insertion of the signal peptide displaces TatB from its 697 
resting state binding site on TatC (grey arrow). TatB movement allows polymerisation of TatA 698 
to be nucleated (step 3). The substrate passes across the membrane facilitated by the TatA 699 
oligomer (step 4). Bottom panel: TatB variants that suppress signal sequence defects 700 
(represented as B*) may be more easily displaced from the resting state binding site. The TatB 701 
variants appear to be on a continuum with TatB F13Y pushing the Tat system into an 702 
assembled state (step 4), whereas Tat systems harboring the weaker suppressing variants 703 
are more likely to correspond to step 3. 704 
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state of the twin arginine translocase 
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Clone TatB substitution/s 
BRE1 L9Q  K103R 
BRE2* L9Q 
BRN2 L9Q  Q134V 
BRN3* L9Q 
BRN4 L10P  V12M 
BRN5 L9P 
BRQ1* K30I  K65R  N99D 
BRQ2* K30I  K65R  N99D 
BRQ3* I36N  S41T 
BRQ4 L9Q  T72A 
BRQ5* I36N  S41T 
BRH1 L9Q  N73K 
BRH2 E8K  L71H 








Table S1. Clones isolated from a tatB mutant library following screening for suppression of 
transport defects of inactive signal peptides. The BRE, BRN, BRQ, BRH, BHH, BKH or BKQ 
clone nomenclature signify substitutions isolated following screening against RE, RN or KQ 
variants of the AmiA signal peptide RR motif, respectively.  




Clone TatAB substitution/s 
AB-1 TatA K23N,TatB I36N, TatB N119I, TatB S164C 
AB-5 TatB L10P 
AB-16 TatB L10P, TatB N73Y 
AB-157 TatB F13Y 
AB-172 TatA A60E, TatA A76R, TatB F13Y 
  
Table S2. Clones isolated from a tatAB mutant library following screening for suppression of 




Strain Relevant genotype Source 
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk–, 
mk+), relA1, supE44, ∆( lac-proAB), 
[F´ traD36, proAB, laqIqZ∆M15] 
 
Promega 
XL10-gold Tetr∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZDM15 Tn10 (Tetr) Amy Camr] 
 
Agilent 
MC4100 F-∆lacU169 araD139 rpsL150 relA1 ptsF rbs flbB5301 (1) 
 
DADE As MC4100, ∆tatABC, ∆tatE (2) 
 
DADE-P as DADE, pcnB1 zad-981::Tn10d (Kanr) (3) 
   
M∆BC MC4100 ∆tatBC (4) 
 
MCDSSAC ∆tatABC MC4100, amiA∆2-33 amiC∆2-32, ∆tatABC::Apra (5) 




MC4100, ∆amiA, ∆amiC, ∆tatABC::Apra This work 
AyBCE MC4100 ∆tatA, attB::PtatAtatA-EAK-eyfpA206K  (4) 
 
AyBCE (tatBL9Q)  
 
As AyBCE, tatBL9Q This work 
AyBCE (tatBL10P)   
 
As AyBCE, tatBL10P This work 
AyBCE (tatBF13Y) 
 
As AyBCE, tatBF13Y This work 
AyBCE (tatBI36N) 
 
As AyBCE, tatBI36N This work 
AyBCE (tatCF94Q)  
 














tatCF94Q)   
 






As AyBCE (tatBI36N, tatCF94Q) 
 
This work 
BL21(DE3) ∆tatABC BL21(DE3), ∆tatABC::Apra This work 
   







BW25113, ∆glpF, ∆tatABC::Apra This work 




Table S3. Strains used and constructed in this study.  
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Plasmid Relevant genotype Source 
pTAT101 Low copy number vector expressing TatABC 
under the control of tat promoter. Kanr. 
(7) 
pTH19kr Low copy-number cloning vector. Backbone of 
pTAT101. 
(8) 
pTAT101-BF6Y As pTAT101, TatB F6Y exchange This work 
pTAT101-BE8K As pTAT101, TatB E8K exchange This work 
pTAT101-BL9P As pTAT101, TatB L9P exchange This work 
pTAT101-BL9Q As pTAT101, TatB L9Q exchange This work 
pTAT101-BL10P As pTAT101, TatB L10P exchange This work 
pTAT101-BF13Y As pTAT101, TatB F13Y exchange This work 
pTAT101-BK30I As pTAT101, TatB K30I exchange This work 
pTAT101-BI36N As pTAT101, TatB I36N exchange This work 
pTAT101-CF94Q As pTAT101, TatC F94Q exchange This work 
pTAT101-CF94A As pTAT101, TatC F94A exchange This work 
pTAT101-CF94D As pTAT101, TatC F94D exchange This work 
pTAT101-CF94G As pTAT101, TatC F94G exchange This work 
pTAT101-CF94K As pTAT101, TatC F94K exchange This work 
pTAT101-CF94P As pTAT101, TatC F94P exchange This work 
pTAT101-CF94R As pTAT101, TatC F94R exchange This work 
pTAT101-CF94S As pTAT101, TatC F94S exchange This work 
pTAT101-CF94Q-BF6Y As pTAT101-CF94Q, TatB F6Y exchange This work 
pTAT101-CF94Q-BE8K As pTAT101-CF94Q, TatB E8K exchange This work 
pTAT101-CF94Q-BL9P As pTAT101-CF94Q, TatB L9P exchange This work 
pTAT101-CF94Q-BL9Q As pTAT101-CF94Q, TatB L9Q exchange This work 
pTAT101-CF94Q-
BL10Q 
As pTAT101-CF94Q, TatB L10P exchange This work 
pTAT101-CF94Q-
BF13Y 
As pTAT101-CF94Q, TatB F13Y exchange This work 
pTAT101-CF94Q-BK30I As pTAT101-CF94Q, TatB K30I exchange This work 
pTAT101-CF94Q-
BI36N 
As pTAT101-CF94Q, TatB I36N exchange This work 
pTAT101-BL9Q F13Y As pTAT101, TatB L9Q, F13Y exchange This work 
pTAT101-BL10P F13Y As pTAT101, TatB L10P, F13Y exchange This work 
pTAT101-BL9Q I36N As pTAT101, TatB L9Q, I36N exchange This work 
pTAT101-BL10P I36N As pTAT101, TatB L10P, I36N exchange This work 
pTAT101-CE103A As pTAT101, TatC E103A exchange This work 
pTAT101-CE103A-
BL9Q 
As pTAT101-CE103A, TatB L9Q exchange This work 
pTAT101-CE103A-
BL10P 
As pTAT101-CE103A, TatB L10P exchange This work 
pTAT101-CE103A-
BF13Y 
As pTAT101-CE103A, TatB F13Y exchange This work 
pTAT101-CE103A-
BI36N 
As pTAT101-CE103A, TatB I36N exchange This work 
pTAT101-CE103K As pTAT101, TatC E103K exchange (7) 
pTAT101-CE103K-
BL9Q 
As pTAT101-CE103K, TatB L9Q exchange This work 
pTAT101-CE103K-
BL10P 





As pTAT101-CE103A, TatB F13Y exchange This work 
pTAT101-CE103K-
BI36N 
As pTAT101-CE103A, TatB I36N exchange This work 
pTAT101-CP48L As pTAT101, TatC P48L exchange (9) 
pTAT101-CP48L- BL9Q As pTAT101-CP48L, TatB L9Q exchange This work 
pTAT101-CP48L - 
BL10P 
As pTAT101-CP48L, TatB L10P exchange This work 
pTAT101-CP48L - 
BF13Y 
As pTAT101-CP48L, TatB F13Y exchange This work 
pTAT101-CM59K As pTAT101, TatC M59K exchange (9) 
pTAT101-CM59K- 
BL9Q 
As pTAT101-CM59K, TatB L9Q exchange This work 
pTAT101-CM59K - 
BL10P 
As pTAT101-CM59K, TatB L10P exchange This work 
pTAT101-CM59K - 
BF13Y 
As pTAT101-CM59K, TatB F13Y exchange This work 
pTAT101-CV145E As pTAT101, TatC V145E exchange (9) 
pTAT101-CV145E- 
BL9Q 
As pTAT101-CV145E, TatB L9Q exchange This work 
pTAT101-CV145E - 
BL10P 
As pTAT101-CV145E, TatB L10P exchange This work 
pTAT101-CV145E - 
BF13Y 
As pTAT101-CV145E, TatB F13Y exchange This work 
pTAT101-CD211K As pTAT101, TatC D211K exchange This work 
pTAT101-CD211K- 
BL9Q 
As pTAT101-CD211K, TatB L9Q exchange This work 
pTAT101-CD211K - 
BL10P 
As pTAT101-CD211K, TatB L10P exchange This work 
pTAT101-CD211K - 
BF13Y 
As pTAT101-CD211K, TatB F13Y exchange This work 
pTAT101-CQ215K As pTAT101, TatC Q215K exchange This work 
pTAT101-CQ215K- 
BL9Q 
As pTAT101-CQ215K, TatB L9Q exchange This work 
pTAT101-CQ215K - 
BL10P 
As pTAT101-CQ215K, TatB L10P exchange This work 
pTAT101-CQ215K - 
BF13Y 
As pTAT101-CQ215K, TatB F13Y exchange This work 
pTAT101 cys less As pTAT101, All 4 cys codons in tatC substituted 
with ala 
(9) 
pTAT101 cys less 
CM205C  
As pTAT101 cys less, TatC M205C exchange (9) 
pTAT101 cys less 
BL9Q CM205C  
As pTAT101 cys less CM205C, TatB L9Q 
exchange 
This work 
pTAT101 cys less 
BL10P CM205C  
As pTAT101 cys less CM205C, TatB L10P 
exchange 
This work 
pTAT101 cys less 
BF13Y CM205C 
As pTAT101 cys less CM205C, TatB F13Y 
exchange 
This work 
pTAT101 cys less 
BI36N CM205C 
As pTAT101 cys less CM205C, TatB I36N 
exchange 
This work 
pTAT101 cys less 
CF94Q M205C 
As pTAT101 cys less CM205C, TatC F94Q This work 
pTAT101 cys less 
BL10P CF94Q M205C 
As pTAT101 cys less CF94Q M205C, TatB L10P This work 
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pTAT101 cys less 
BF13Y CF94Q M205C 
As pTAT101 cys less CF94Q M205C, TatB F13Y This work 
pQE80-CueO As pQE80, carrying cueOhis (4) 
pQE80-CueOKKh As pQE80-CueO, CueO R3K, R4K exchange (4) 
pTAT1d Medium copy number vector expressing TatABC 
under the control of tat promoter. Ampr. 
(10) 
pUNIPROM pT7.5 vector carrying a tat promoter. Backbone of 
pTAT1d 
(11) 
pTAT1d-CF94Q As pTAT1d, TatC F94Q exchange This work 
pTAT1d-CF94A As pTAT1d, TatC F94A exchange This work 
pTAT1d-CF94D As pTAT1d, TatC F94D exchange This work 
pTAT1d-CF94G As pTAT1d, TatC F94G exchange This work 
pTAT1d-CF94K As pTAT1d, TatC F94K exchange This work 
pTAT1d-CF94P As pTAT1d, TatC F94P exchange This work 
pTAT1d-CF94R As pTAT1d, TatC F94R exchange This work 
pTAT1d-CF94S As pTAT1d, TatC F94S exchange This work 
pTAT1d-CF94Q-BL9Q As pTAT1d-CF94Q, TatB L9Q exchange This work  
pTAT1d-CF94Q-BL10P As pTAT1d-CF94Q, TatB L10P exchange This work 
pTAT1d-CF94Q-BF13Y As pTAT1d-CF94Q, TatB F13Y exchange This work  
pTAT1d-CF94Q-BI36N As pTAT1d-CF94Q, TatB I36N exchange This work 
pTATBC1d pUNIPROM carrying tatBC This work 
pSUAmiA pSU18 carrying amiA (12) 
pSUAmiA-RD As pSUAmiA, R14D exchange This work 
pSUAmiA-RE As pSUAmiA, R14E exchange This work 
pSUAmiA-RH As pSUAmiA, R14H exchange This work 
pSUAmiA-RN As pSUAmiA, R14N exchange This work 
pSUAmiA-RQ As pSUAmiA, R14Q exchange This work 
pSUAmiA-KH As pSUAmiA, R13K, R14H exchange This work 
pSUAmiA-KQ As pSUAmiA, R13K, R14Q exchange This work 
pSUAmiA-HH As pSUAmiA, R13H, R14H exchange This work 
pSUSufIss-mAmiA pSU18, carrying SufIss-mAmiA This work 
pSUSufIss-mAmiA-RD As pSUSufIss-mAmiA, SufI R6D exchange This work 
pSUSufIss-mAmiA-RE As pSUSufIss-mAmiA, SufI R6E exchange This work 
pSUSufIss-mAmiA-RH As pSUSufIss-mAmiA, SufI R6H exchange This work 
pSUSufIss-mAmiA-RN As pSUSufIss-mAmiA, SufI R6N exchange This work 
pSUSufIss-mAmiA-RQ As pSUSufIss-mAmiA, SufI R6Q exchange This work 
pSUSufIss-mAmiA-KH As pSUSufIss-mAmiA, SufI R5K, R6H exchange This work 
pSUSufIss-mAmiA-KQ As pSUSufIss-mAmiA, SufI R5K, R6Q exchange This work 
pSUSufIss-mAmiA-KK As pSUSufIss-mAmiA, SufI R5K, R6K exchange This work 
pSUSufIss-mAmiA-HH As pSUSufIss-mAmiA, SufI R5H, R6H exchange This work 
pSUSufIssnoH-mAmiA As pSUSufIss-mAmiA, sufI ∆11-21 This work 
pSUmAmiA As pSUAmiA, amiA ∆2-34 This work 
pFAT75∆A-BC As pQEABC, but with tatA gene in frame deleted (13) 
pFAT75∆A-BC 
BE8K 
As pFAT75∆A-BC, TatB E8K exchange This work 
pFAT75∆A-BC 
BF13Y 
As pFAT75∆A-BC, TatB F13Y exchange This work 
pFAT75∆A-BC 
BI36N 
As pFAT75∆A-BC, TatB BI36N exchange This work 






As pFAT75∆A-BC CF94Q, TatB L9Q exchange This work 
pFAT75∆A-BC 
BL10P CF94Q 
As pFAT75∆A-BC CF94Q, TatB L10P exchange This work 
pFAT75∆A-BC 
BF13Y CF94Q 
As pFAT75∆A-BC CF94Q, TatB F13Y exchange This work 
pFAT75∆A-BC 
BI36NC CF94Q 
As pFAT75∆A-BC CF94Q, TatB I36N exchange This work 

























As pFAT75∆A-BC, TatBF13Y exchange This work 
pFAT75∆A-BF13YC-
AmiARDhis 




















As pFAT75∆A-BC also producing C-terminally 




As pFAT75∆A-BC-mAmiAhis, TatBF13Y 
exchange 
This work 
pQE70-mAmiA pQE70 producing C-terminally his-tagged mature 
AmiA 
This work 
pQE70-mAmiC pQE70 producing C-terminally his-tagged mature 
AmiC 
This work 
pSufIss-GFPhis As pCDFDuet-1, carrying synthetic SufI signal 
sequence-fused GFPhis 
This work 
pSufIssRD-GFPhis As pSufIss-GFPhis, SufI R6D exchange This work 
pSufIssRN-GFPhis As pSufIss-GFPhis, SufI R6N exchange This work 
pSufIssKK-GFPhis As pSufIss-GFPhis, SufI R5K, R6K exchange This work 
pQE80 sufIhis pQE80 carrying sufIhis This work 
pQE80 RDsufIhis pQE80 sufIhis SufI R6D exchange This work 
pQE80 RNsufIhis pQE80 sufIhis SufI R6N exchange This work 
pQE80 KQsufIhis pQE80 sufIhis SufI R5K, R6Q exchange This work 
pMAK705 Cloning vector with a temperature-sensitive 
replicon 
(14) 
pMAK-AupBC As pMAK705, carrying 500 bp upstream 
sequence of tatA and tatBC sequence 
This work 
pMAK-AupBC-BL9Q As pMAK-AupBC, TatB L9Q exchange This work 
pMAK-AupBC-BL10P As pMAK-AupBC, TatB L10P exchange This work 
pMAK-AupBC-BF13Y As pMAK-AupBC, TatB F13Y exchange This work 
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pMAK-AupBC-BI36N As pMAK-AupBC, TatB I36N exchange This work 
pMAK-AupBC-CF94Q As pMAK-AupBC, TatC F94Q exchange This work 
pMAK-AupBC- BL9Q  
CF94Q 
As pMAK-AupBC, TatB L9Q, TatC F94Q 
exchange 
This work 
pMAK-AupBC- BL10P  
CF94Q 
As pMAK-AupBC, TatB L10P, TatC F94Q 
exchange 
This work 
pMAK-AupBC- BF13Y  
CF94Q 
As pMAK-AupBC, TatB F13Y, TatC F94Q 
exchange
This work
pMAK-AupBC- BI36N  
CF94Q 
As pMAK-AupBC, TatB I36N, TatC F94Q 
exchange 
This work 
pBAD24 Arabinose-inducible protein expression vector (15) 
pBADTatABChis As pBAD24, carrying tatABChis  This work  
pBADTatABChis-BL9Q As pBADTatABChis, TatB L9Q exchange This work 
pBADTatABChis-BL10P As pBADTatABChis, TatB L10P exchange This work 
pBADTatABChis-
BF13Y 
As pBADTatABChis, TatB F13Y exchange This work 
pBADTatABChis-BI36N As pBADTatABChis, TatB I36N exchange This work 
pBAD22SecY(∆plug)EG pBAD22, producing SecY(∆codons62-72)EG Ian Collinson 
p101C*TatBC Low copy vector for expression of tatBC from the 
tatA promoter with a modified RBS 
(4) 
p101C*BCflag p101C*BC derivative producing TatB and C-
terminally flag-tagged TatC 
This work 
p101C*BCflag E8K As p101C*BCflag, TatB E8K exchange This work 
p101C*BCflag F13Y As p101C*BCflag, TatB F13Y exchange This work 
 
Table S4. Plasmids used and constructed in this study   
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amiA-mF GGCCAGCGCAAAAGACGAACTTTTAAAAACC  






































C-F94S1  GGTGTGGGCATCTATCGCCCCAG 
C-F94S2  CTGGGGCGATAGATGCCCACACC 
C-F94A1  GGTGTGGGCAGCGATCGCCCCAG 





























tatB E8K 1 GATATCGGTTTTAGCAAACTGCTATTGG 









C-V145E1  CGGAAGGGGAACAGGTATCCAC 
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Supplementary Figure Legends 
Figure S1. Substitutions of the twin arginines in the AmiA signal peptide prevent growth 
in the presence of SDS. Strain MCDSSAC ∆tatABC producing wild type tatABC from plasmid 
pTAT1d and either wild type (‘RR’) or signal peptide point-substituted AmiA, as indicated, from 
pSUAmiA. The strain and plasmid combinations were cultured overnight in LB medium 
supplemented with chloramphenicol and ampicillin (for plasmid selection), after which they 
were streaked onto LB agar containing the same antibiotics, with and without the addition of 
2% SDS and incubated for 16 hr at 37°C. 
Figure S2. TatB variants are able to restore Tat transport to a range of defective twin 
arginine substitutions in the AmiA signal sequence. Growth of MCDSSAC ∆tatABC 
coproducing the indicated TatB variants (with wild type tatA and tatC) from pTAT101, or the 
empty plasmid pTH19kr (indicated by ‘tat’) alongside signal peptide variants of AmiA, on LB 
agar supplemented with chloramphenicol and kanamycin, with and without the addition of 2% 
SDS as indicated. An 8l aliquot of each strain/plasmid combination following aerobic growth 
to an OD600 of 1.0 was spotted and incubated for 16 hr at 37°C. A. Individual signal peptide 
substitutions of AmiA (indicated to the left of each panel) were tested against the TatB 
suppressors F6Y, L9P, L9Q, L10P, F13Y, K30I and I36N. B. The TatB E8K suppressor was 
tested for the ability to suppress the indicated AmiA signal peptide substitutions. 
Figure S3. TatB variants are able to restore Tat transport to a range of defective twin 
arginine substitutions in the SufI signal sequence. Growth of MCDSSAC ∆tatABC 
coproducing the indicated TatB variants (with wild type tatA and tatC) from pTAT101, or the 
empty plasmid pTH19kr (indicated by ‘tat’) alongside signal peptide variants of SufI fused to 
the AmiA mature domain, on LB agar supplemented with chloramphenicol and kanamycin, 
with and without the addition of 2% SDS as indicated. An 8l aliquot of each strain/plasmid 
combination following aerobic growth to an OD600 of 1.0 was spotted and incubated for 16 hr 
at 37°C. A. Individual signal peptide substitutions of AmiA (indicated to the left of each panel) 
were tested against the TatB suppressors F6Y, L9P, L9Q, L10P, F13Y, K30I and I36N. B. The 
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TatB E8K suppressor was tested for the ability to suppress the indicated AmiA signal peptide 
substitutions 
Figure S4. A subset of amino acid substitutions at TatCF94 abolish Tat activity when 
produced at medium and low copy number. A and C. Growth of DADE coproducing either 
wild type TatABC (Tat+), wild type TatAB alongside F94-substituted TatC or the cognate empty 
plasmid (Tat-) on LB agar containing 2% SDS. A single colony of each strain/plasmid 
combination was resuspended in 30l of PBS and an 8l aliquot was spotted onto LB agar 
supplemented with appropriate antibiotics, along with 2% SDS as indicated. Plates were 
incubated for 16 hr at 37°C. B and D. Detection of TatC protein present in membrane fractions 
of the same strain and plasmid combinations as in A. and C., respectively, by Western 
immunoblot with anti-TatC antiserum. A total of 5g membranes was loaded per lane for TatC 
produced from pTAT1d (B) and 20g per lane for membranes produced from strains harboring 
pTAT101 derivatives (D).  
Figure S5. TatB variants cannot supress TatC inactivating substitutions outside of the 
signal peptide binding site. Growth of DADE (tatABCD, tatE) coproducing wild type TatA 
alongside and the indicated substitution in TatB alongside either of TatC P48L, TatC M59K, 
TatC V145E, TatC D211K or TatC Q215K as indicated, from plasmid pTAT101 on LB agar or 
LB agar containing 2% SDS. A single colony of each strain/plasmid combination was 
resuspended in 30l of PBS and an 8l aliquot was spotted onto LB agar supplemented with 
appropriate antibiotics, along with 2% SDS as indicated, and incubated for 16 hr at 37°C. 
Figure S6. The suppressive effect of the TatB variants is not additive and mature AmiC 
is not exported in the presence of the TatB F13Y suppressor. A. Growth of DADE 
coproducing either wild type TatABC (Tat+), wild type TatAB alongside F94-substituted TatC 
or the cognate empty plasmid (Tat-) on LB agar or LB agar containing 2% SDS. B. Growth of 
MCDSSAC ∆tatABC coproducing the indicated TatB variants (with wild type tatA and tatC) 
from pTAT101, or the empty plasmid pTH19kr (indicated by ‘tat’) alongside the RN or KK 
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signal peptide variants of SufI fused to the AmiA mature domain, as indicated, on LB agar with 
or without the addition of 2% SDS. C. Strain MC4100 ∆amiA ∆amiC ∆tatABC coproducing 
either wild-type TatB or TatB F13Y (with wild type tatA and tatC) from pTAT101 and the AmiA 
or AmiC mature domains (from pQE70-mAmiA or pQE70-mAmiC, respectively) on LB agar or 
LB agar containing 2% SDS. In each case a single colony of each strain/plasmid combination 
was resuspended in 30l of PBS and an 8l aliquot was spotted onto LB agar supplemented 
with appropriate antibiotics, along with 2% SDS where indicated. Plates were incubated for 16 
hr at 37°C. 
Figure S7. The TatB suppressors support export of his-tagged SufI with its native signal 
peptide. A. and B. E. coli strain DADE producing wild type TatA and TatC and the indicated 
TatB variants alongside wild-type SufI-his or the indicated signal-peptide variants were 
fractionated into whole cell (upper panels) and periplasm (lower panels) fractions, then 
analysed by Western blot with anti-6X His tag® or anti-RNA polymerase  subunit antibodies 
(cytoplasmic control protein). wc – whole cell.  
Figure S8. TatBC and SufIss-GFP-His twin-arginine variants are detectable in whole cell 
samples. A. and B. Cells producing SufIss-GFP-His with the wild type (RR) or twin-arginine 
substituted SufI signal peptide, as indicated, alongside TatC and either wild type TatB or the 
E8K, F13Y or I36N substituted variants, or C. and D. Cells producing SufIss-GFP-His with the 
wild type SufI signal peptide along with either wild type TatBC, the TatC F94Q allele along 
with either wild type TatB or the L9Q, L10P, F13Y or I36N substituted variants, or the TatC 
E103K allele along with either wild type TatB or the L9Q, L10P, F13Y or I36N substituted 
variants, as indicated were harvested and resuspended in PBS. A. and C. The fluorescence 
intensity and OD600 of the samples were measured using a plate reader and the 
Fluorescence/OD600 plotted for each sample. B. and D. 20 μl of each cell suspension was 
taken, all samples were normalized to the same OD600 and then analysed by SDS-PAGE 
followed by western blot using a TatB-TatC mixed antibody. 
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Figure S9. TatBC complexes containing the TatB F13Y suppressor do not co-purify with 
signal peptide variants of AmiA. C-terminally his-tagged wild type AmiA, twin-arginine 
substituted AmiA or signal sequence-less AmiA, as indicated was co-produced alongside wild 
type TatBC or TatBF13Y/TatC and purified using nickel beads from digitonin–treated cell 
extracts. Aliquots of the load and elution fractions were subject to SDS-PAGE followed by 
Western blot using either anti-His, anti-TatB and TatC antibodies. 
Figure S10. TatB variants are extracted from the membrane with digitonin. Membrane 
suspensions (containing equivalent amounts of total protein) from strain DADE coproducing 
either wild type TatABC or wild type TatA and TatC alongside the indicated amino acid variant 
of TatB were solubilized by addition of 2% digitonin and incubation on ice for 30 min. Samples 
total membranes and digitonin solubilized material (each containing 10g protein) were 
analysed by SDS-PAGE followed by western blotting with anti-TatA, anti-TatB or anti-TatC 
antibodies as indicated. 
Figure S11. Constitutive oligomerisation of TatA is not promoted by the TatB L9Q, L10P 
or I36N substitutions. Fluorescence images of TatA-YFP in representative cells of A. strains 
AyBCE or AyBCF94QE (encoding chromosomal TatC F94Q) in the presence (pAmiA) or 
absence of plasmid-encoded wild type AmiA, as indicated (reproduced from Fig 5A). B. strains 
AyBL9QCE (encoding chromosomal TatB L9Q), AyBL10PCE (encoding chromosomal TatB 
L10P) and AyBI36NCE (encoding chromosomal TatB I36N) or the same strains additionally 
harboring the chromosomally-encoded TatC F94Q substitution. Scale bar: 1 μm. Note that the 
pictures in panel A are identical to those in Fig 5A and were included here to provide a direct 
comparison with panel B.  
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